Answers are grounded in this paper and cite their sources.
Research reveals mesenchymal gene signature predicts worse survival in synovial sarcoma, suggesting new treatment strategies.
This study demonstrates a correlation between mesenchymal gene expression signatures and increased metastatic risk in SS. EMT status, derived from primary tumor profiling at diagnosis, may serve as a potential prognostic biomarker. These findings support further investigation into EMT as a stratification tool for tailoring treatment intensity and surveillance strategies in SS.
No takes yet. Share an insight, caveat, or question.
Jagosky et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: